Introduction {#sec1}
============

Many organic compounds bearing the N-oxide structural motif are known as promising building blocks in the design of advanced materials, agrochemicals, cosmetics, and pharmaceuticals.^[@ref1]^ The prevalence of the N-oxide scaffold in prospective organic compounds seems to be associated with the specific changes in properties of heterocyclic N-oxides relative to their parent compounds.^[@ref2]^ Currently, this distinguishing feature of the N^+^--O^--^ motif is often used in retrosynthetic schemes as an elegant tool to induce the desired physical and chemical properties, as well as pharmacological activities and other beneficial outcomes for the target compounds. In addition, the N-oxide function is generally considered as one of the privileged scaffolds in the structures of both intermediates and final products exhibiting a variety of therapeutic effects, such as antibacterial, antiviral, anticancer, antiprotozoal, antifungal, neuroprotective, and other activities.^[@ref3]^

Among the known biologically active and medicinally important compounds bearing the N-oxide function, derivatives in which the −C=N^+^--O^--^ pharmacophore fragment is partly involved in a (hetero)aromatic ring ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) attract special attention. For instance, chlordiazepoxide **I** is a sedative and hypnotic medication of the benzodiazepine family, which is commonly used for the treatment of anxiety, insomnia, and to withdraw symptoms from alcohol and/or drug abuse.^[@ref4]^ 1,7-Naphthyridine *N*-oxide **II**, the p38α mitogen-activated protein kinase inhibitor, is considered to be an efficient agent for therapy of autoimmune and inflammatory diseases.^[@ref5]^ Indoline derivative **III** shows neuroprotective spin-trapping properties and prevents cell death under oxidative stress conditions.^[@cit3j]^ Furoxane **IV**, being a good nitric oxide donor, proved to possess an increased procognitive activity and cytotoxicity.^[@ref6]^ 2,2′-Pyridylisatogen **V** is a good antioxidant agent with neuroprotective activity.^[@ref7]^

![Prospective N-oxide-based pharmaceuticals and drug candidates.](ao-2018-02916x_0006){#fig1}

It is worth noting that an overwhelming majority of practically interested organic compounds have turned out to be bi- and/or polyfunctional derivatives in which the structural subunits are linked to each other through the carbon--carbon bonds.^[@ref8]^ In this respect, one of the key challenges for modern organic synthesis is the development of simple and convenient approaches to obtain the target organic ensembles containing various functional building blocks through the construction of the C--C bonds.^[@ref9]^ The effectiveness and expediency of the methods used can be easily assessed, taking into account the compliance of the latter with the basic principles of green chemistry, such as atom and step economy.^[@ref10]^ Currently, the green chemistry-oriented C--H functionalization methodology,^[@ref11],[@ref12]^ which allows one to convert C(sp^2^)--H bonds of the starting materials into C--C bonds of the target products without any preliminary functionalization of the reactive partners, is considered to be a useful synthetic tool because it provides the environmental-friendly solutions in the design of bi- and/or polyfunctional organic compounds of various architectures.

One of the most promising approaches based on the C(sp^2^)--H functionalization methodology suggests using the transition-metal-catalyzed oxidative C--H/C--H coupling reactions between (hetero)arenes.^[@cit8a],[@cit8b],[@ref12]^ These industrially important processes, being atom- and stage-efficient alternative to both C--X/C--Y and C--H/C--X(Y) coupling strategies \[X = (pseudo)halide, Y = metal\], are actively used to functionalize aromatic and heteroaromatic (π-excessive and π-deficient) compounds, including azine N-oxides and other azine-activated forms. At the same time, the number of C--H/C--H coupling reactions studied in the chemistry of nonaromatic nitrogen-containing compounds has still rather been limited. Indeed, a few examples of the direct C--H functionalization of cyclic aldonitrones lacking an aromatic π-conjugated system are presented by the following reactions of 2*H*-imidazole 1-oxides: uncatalyzed by transition metals (i) oxidative C--H/C--Li coupling with organometallics,^[@ref13]^ (ii) metalation followed by coupling with electrophiles,^[@ref14]^ (iii) eliminative C--H/C--H coupling with azoles,^[@ref15]^ and (iv) Pd(II)-catalyzed oxidative C--H/C--H coupling with indoles.^[@cit15b]^ It should be noted that in case of oxidative reactions (i, ii, and iv), the retention of the N-oxide group in the coupling products is observed, whereas the eliminative process (iii) has been shown to result in the formation of 2*H*-imidazoles with the loss of the N-oxide function.

This study is aimed at the development of a facile and effective synthetic approach for the direct C(sp^2^)--H bond functionalization of cyclic aldonitrones with fragments of pyrroles and thiophenes to obtain novel heterocyclic ensembles, 5-heteroaryl-substituted 2*H*-imidazole 1-oxides, in good yields.

Results and Discussion {#sec2}
======================

The methodology for the direct nucleophilic C(sp^2^)--H bond functionalization in the series of nonaromatic 2*H*-imidazole 1-oxides **1** has first been used as the main synthetic strategy to the family of novel C(5)-modified 2*H*-imidazole derivatives. In particular, the Pd(II)-mediated C--H/C--H cross-coupling reactions of cyclic nitrones **1a--c** with a variety of π-excessive pyrroles and thiophenes **2a--g** bearing both electron-donating and electron-withdrawing substituents have been carried out. The elaborated cross-dehydrogenative C--C coupling reactions have been shown to result in the formation of previously unknown biheterocyclic ensembles containing the N-oxide group in the imidazole ring in 40--78% yields ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

###### Scope and Yields for the Pd(II)-Mediated Oxidative Cross-Coupling Reaction of 2*H*-Imidazole 1-Oxides **1a--c** with Pyrroles and Thiophenes **2a--g**[a](#t1fn1){ref-type="table-fn"}^,^[b](#t1fn2){ref-type="table-fn"}

![](ao-2018-02916x_0001){#fx1}

Reaction conditions: 2*H*-imidazole 1-oxides **1a--c** (1 mmol), pyrroles and thiophenes **2a--g** (2 mmol), Pd(OAc)~2~ (0.1 mmol), Cu(OAc)~2~·H~2~O (1.5 mmol), and pyridine (1.5 mmol) in 1,4-dioxane (5 mL) at 110--120 °C for 24 h.

Isolated yields.

A special attention has been focused on the conditions optimization for these cross-coupling reactions by varying the basic parameters, such as molar ratio of the coupling partners **1** and **2**, amounts of catalyst Pd(OAc)~2~ and oxidant Cu(OAc)~2~, and the reaction time. Initially, the conditions that had earlier been used for the direct C--H/C--H coupling of aldonitrones with indoles were checked.^[@cit15b],[@ref16]^ The interaction of aldonitrone **1b** with thiophene **2b** proceeding in 1,4-dioxane at 120 °C in the presence of pyridine was chosen as the model reaction ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). As a result of these experiments, the best yield (75%) of the coupling product **3g**, 5-(5-acetylthiophen-2-yl)-2-ethyl-2-methyl-4-phenyl-2*H*-imidazole 1-oxide, has been achieved after 24 h with the following ratio of reagents ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, entry 9): 2*H*-imidazole **1b** (1 mmol), thiophene **2b** (2 mmol), palladium (0.1 mmol) and copper (1.5 mmol) acetates.

###### Optimization of Conditions for the Palladium(II)-Catalyzed Oxidative Cross-Coupling Reaction of 2*H*-Imidazole 1-Oxide **1b** with Thiophene **2b**

  entry   **1b** (mmol)   **2b** (mmol)   Pd(OAc)~2~ (mmol)   Cu(OAc)~2~·H~2~O (mmol)   reaction time (h)   yield of **3g** (%)
  ------- --------------- --------------- ------------------- ------------------------- ------------------- ---------------------
  1       1.0             1.0             0.02                1.0                       2                   36
  2       1.0             1.0             0.02                1.0                       4                   42
  3       1.0             1.0             0.02                1.0                       8                   45
  4       1.0             1.0             0.06                1.0                       12                  52
  5       1.0             1.0             0.1                 1.0                       24                  58
  6       1.0             1.5             0.02                1.0                       2                   36
  7       1.0             2.0             0.06                1.0                       12                  54
  8       1.0             2.5             0.1                 1.0                       24                  57
  **9**   **1.0**         **2.0**         **0.1**             **1.5**                   **24**              **75**
  10      1.0             2.0             0.1                 2.5                       32                  73
  11      1.0             0.5             0.1                 1.5                       24                  72
  12      1.0             0.3             0.1                 1.5                       24                  70

In accordance with the modern concept for transition-metal-catalyzed cross-dehydrogenative coupling (CDC) reactions,^[@ref17]^ the oxidative C--H/C--H coupling of 2*H*-imidazole 1-oxides with π-excessive heterocyclic compounds, such as pyrroles or thiophenes, seems to be a cyclic redox process. The organopalladium intermediates bearing the C--Pd bond are supposed to be formed, and the cyclic redox transformations of palladium catalyst Pd(II) → Pd(0) → Pd(II) take place in this case. It should also be mentioned that the data of mechanistic studies on these transition-metal-catalyzed cross-dehydrogenative coupling reactions suggest two plausible ways for palladium-induced activation of the C--H bond in (hetero)arenes, namely, electrophilic aromatic metalation and concerted metalation--deprotonation pathways.^[@ref18]^

To gain insight into the CDC reaction mechanism and elucidate the competiveness for palladation of the reactive partners, the H/D exchange experiments have been performed ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) using NMR spectroscopy. Herein, the previously described experimental protocol^[@ref19]^ has been applied to perform a series of experiments separately with 2*H*-imidazole 1-oxide **1a** and 2-acetylthiophene **2b** by using the standard conditions: Pd(OAc)~2~, 0.1 mmol; Cu(OAc)~2~·H~2~O, 1.5 mmol; 1,4-dioxane, 5 mL; heating at 110--120 °C for 24 h, and D~2~O, 20 mmol, as a deuterium source. The data of the ^1^H NMR experiments performed are summarized in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}.

![H/D Exchange Experiments for Cross-Dehydrogenative Coupling Partners **1a** and **2b**](ao-2018-02916x_0003){#sch1}

###### Conditions and Results of the H/D-Exchange Control Experiments[a](#t3fn1){ref-type="table-fn"}

                    conditions                      
  ------- ---- ---- ------------ ---- ---- -------- -------------------
  1       \+   --   --           \+   \+   1.00:0   --
  2       --   \+   --           \+   \+   --       1.00:0
  3       \+   --   \+           \+   \+   1.00:0   --
  **4**   --   \+   \+           \+   \+   --       **0.65**:**0.35**
  5       --   \+   \+           --   \+   --       1.00:0
  **6**   --   \+   \+           \+   --   --       **0.65**:**0.35**

The resulted reaction mixtures were analyzed by ^1^H NMR spectroscopy in dimethyl sulfoxide (DMSO)-*d*~6~ at 295 K.

In the first instance, the role of pyridine in the process has been studied. The control experiments with compounds **1a** and **2b** carried out without pyridine have afforded no deuterated products ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 1 and 2), thus showing the crucial role of pyridine as a ligand in these transformations. Indeed, in analogous experiments proceeding in the presence of pyridine the hydrogen--deuterium exchange was shown to occur in case of 2-acetylthiophene **2b** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 3 and 4). Therefore, it has been suggested that the initial step of the cross-coupling process under discussion is the formation of the organopalladium intermediate derived from heteroaromatic compound **2** (pyrrole or thiophene) rather than from nitrone **1**. To confirm this hypothesis, attempts to deuterate 2-acetylthiophene **2b** in the absence of either palladium catalyst Pd(OAc)~2~ or oxidant Cu(OAc)~2~ have been undertaken. As expected, no hydrogen--deuterium exchange has been found to be occur in the absence of palladium acetate ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 5), whereas in the absence of copper acetate, compound **2b** was deuterated up to 35% ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 6). These data appear to support the hypothesis that the covalent C--Pd bond is formed at the first step of the cross-coupling process deriving from the reaction of thiophene/pyrrole **2** with palladium acetate. In addition, the experimental data obtained have enabled us to refute the other versions of the hydrogen--deuterium exchange process associated with acid--base interactions of **2** with pyridine. as well as with the formation of organocopper intermediates. To illustrate it, the distinctive fragments of the ^1^H NMR spectra of the reaction mixtures after furnishing the H/D-exchange control experiments with 2-acetylthiophene **2b** are shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.

![Fragments of the ^1^H NMR spectra of the resulted reaction mixtures for H/D-exchange control experiments in case of 2-acetylthiophene **2b** in the absence (a) ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 2) and the presence (b) of pyridine ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 4).](ao-2018-02916x_0002){#fig2}

On the basis of the experimental results and the analysis of the literature data,^[@ref20],[@ref21]^ a plausible mechanism for the described cross-coupling reactions has been advanced ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). It suggests that the formation of above-mentioned organopalladium intermediates **A** takes place at the first step due to the interaction of heteroaromatic compounds **2a--g** with palladium(II) and pyridine molecules, which act as ligands (L*~n~*) that stabilize the organometallic intermediates.^[@ref18]^ Intermediates **A** seem to be coordinated with the oxygen center of 2*H*-imidazole 1-oxides **1a--c** through the ligand-exchange mechanism to form intermediates **B**. The chelate-controlled functionalization of the nitrone C(1)--H bond through the concerted metalation/deprotonation transformations^[@cit20b],[@ref21]^ appears to afford the intermediates **C**. Further reductive elimination has likely to form the desired biheterocyclic products **3a--r** and Pd(0). The latter can be transformed into Pd(II) form via oxidation with copper(II) acetate, thus undergoing the recycling process.

![Plausible Catalytic Cycle for the Cross-Dehydrogenative Coupling Reactions of 2*H*-Imidazole 1-Oxides **1a--c** with Pyrroles and Thiophenes **2a--g**](ao-2018-02916x_0004){#sch2}

Conclusions {#sec3}
===========

In summary, an original atom- and step-economical approach based on the palladium-mediated oxidative cross-dehydrogenative C--C coupling reactions (CDC) has successfully been applied for the synthesis of previously unknown biheterocyclic N-oxide ensembles. The mechanistic features of the C--H activation process have been highlighted, and the series of novel 5-heteroarylated 2*H*-imidazole 1-oxides, which are of particular interest in the design of bioactive molecules and advanced materials, has been obtained and fully characterized. The developed methodology proved to be an efficient synthetic tool to provide C(sp^2^)--H/C(sp^2^)--H cross-coupling of 2*H*-imidazole 1-oxides with π-excessive heterocyclic compounds, such as pyrroles or thiophenes, affording the target products in yields up to 78%.

Experimental Section {#sec4}
====================

General Experimental Methods {#sec4.1}
----------------------------

The NMR (^1^H, 400 MHz and ^13^C, 100 MHz) spectra were recorded on a Bruker AVANCE II spectrometer in DMSO-*d*~6~ using tetramethylsilane as an internal standard. The ^13^C NMR spectra were recorded in a mode of attached proton test with full proton decoupling. The mass spectra (EI) were obtained by means of a SHIMADZU GCMS-QP2010 Ultra mass spectrometer. The infrared spectra were recorded on a Bruker Alpha FT-IR spectrometer. The elemental analysis was fulfilled on a CHNS/O analyzer. The reactions course was monitored by thin-layer chromatography (0.25 mm silica gel plates, Merck 60F 254). Column chromatography was carried out on 220--440 mesh silica gel (60, 0.035--0.070 mm).

General Procedure for the Synthesis of 3a--r {#sec4.2}
--------------------------------------------

In a similar manner to the previously described procedure,^[@cit15b]^ a mixture of aldonitrone **1a--c** (1 mmol), pyrrole or thiophene **2a--g** (2 mmol), palladium(II) acetate (22.5 mg, 0.1 mmol), copper(II) acetate monohydrate (300 mg, 1.5 mmol), and pyridine (0.12 mL, 1.5 mmol) in 1,4-dioxane (5 mL) was refluxed at 110--120 °C for 24 h. The cooled to ambient temperature reaction mass was then subjected to flash chromatography on neutral Al~2~O~3~ using ethyl acetate as an eluent. The resulted eluate was concentrated in vacuo to dryness. The formed residue was chromatographed using silica gel column technique with the EtOAc--hexane gradient elution. The obtained eluate was finally concentrated in vacuo.

2,2-Dimethyl-4-phenyl-2*H*-imidazole 1-oxide **1a**, 3-phenyl-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-oxide **1c**,^[@ref22]^ and 2-ethyl-2-methyl-4-phenyl-2*H*-imidazole 1-oxide **1b**([@cit15b]) were prepared according to the published procedures. Thiophene **2a**, 2-acetylthiophene **2b**, pyrrole **2c**, 1-methylpyrrole **2d**, 2-acetyl-1*H*-pyrrole **2e**, 2-phenyl-1*H*-pyrrole **2f**, 4,5,6,7-tetrahydro-1*H*-indole **2g**, palladium(II) acetate, copper(II) acetate monohydrate, pyridine, and 1,4-dioxane were purchased from commercial sources.

Characterization Data for All Products (3a--r) {#sec4.3}
----------------------------------------------

### 5-(5-Acetylthiophen-2-yl)-2,2-dimethyl-4-phenyl-2*H*-imidazole 1-Oxide (**3a**) {#sec4.3.1}

Yield: 200 mg (64%), mp = 137--142 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.61 (s, 6H); 2.53 (s, 3H); 6.96 (d, 1H, *J* = 4.16); 7.57--7.70 (m, 5H); 7.81 (d, 1H, *J* = 4.12) ppm. ^13^C NMR (DMSO-*d*~6~): δ 24.0 (CH~3~); 26.8 (CH~3~); 99.5 (C); 127.9 (CH); 128.2 (CH); 128.5 (CH); 130.5 (CH); 131.4 (C); 132.0 (CH); 133.0 (C); 133.9 (C); 142.2 (C); 164.5 (C); 191.3 (C) ppm. IR (DRA): ν 3850, 3243, 3188, 3167, 3141, 2978, 1602, 1579, 1519, 1442, 1133, 917, 735, 696, 580 cm^--1^. MS (EI): *m*/*z* 312 \[M\]^+^. Anal. calcd for C~17~H~16~N~2~O~2~S: C, 65.36; H, 5.16; N, 8.97; O, 10.24; S, 10.26. Found: C, 64.89; H, 4.81; N, 7.82.

### 2,2-Dimethyl-4-phenyl-5-(thiophen-2-yl)-2*H*-imidazole 1-Oxide (**3b**) {#sec4.3.2}

Yield: 151 mg (56%), mp = 107--112 °C. *R~f~* 0.3 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.59 (s, 6H); 6.99 (d, 1H, *J* = 3.12); 7.08 (t, 1H, *J* = 4.08); 7.58--7.68 (m, 5H); 7.74 (d, 1H, *J* = 4.64) ppm. ^13^C NMR (DMSO-*d*~6~): δ 24.1 (CH~3~); 98.6 (C); 126.5 (CH); 127.4 (CH); 127.6 (C); 128.2 (CH); 128.3 (CH); 128.5 (CH); 130.5 (CH); 131.5 (C); 133.5 (C); 165.2 (C) ppm. IR (DRA): ν 1478, 1446, 1420, 1384, 1367, 1354, 1318, 1244, 1228, 1194, 1155, 765, 742, 727, 697, 646 cm^--1^. MS (EI): *m*/*z* 270 \[M\]^+^. Anal. calcd for C~15~H~14~N~2~OS: C, 66.64; H, 5.22; N, 10.36; O, 5.92; S, 11.86. Found: C, 66.62; H, 5.13; N, 9.91.

### 2,2-Dimethyl-5-(1-methyl-1*H*-pyrrol-2-yl)-4-phenyl-2*H*-imidazole 1-Oxide (**3c**) {#sec4.3.3}

Yield: 208 mg (78%), mp = 97--102 °C. *R~f~* 0.1 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.59 (s, 6H); 3.49 (s, 3H); 6.01--6.02 (m, 1H); 6.10--6.12 (m, 1H); 7.00--7.01 (m, 1H); 7.39--7.43 (m, 2H); 7.48--7.55 (m, 3H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 24.4 (CH~3~); 34.7 (CH~3~); 99.0 (C); 108.1 (CH); 112.5 (CH); 118.4 (C); 125.3 (CH); 127.8 (CH); 128.2 (CH); 130.0 (C); 130.9 (CH); 131.9 (C); 165.1 (C) ppm. IR (DRA): ν 1544, 1502, 1444, 1429, 1386, 1345, 1329, 1245, 1227, 1182, 1155, 1094, 1059, 1028, 946, 775, 733, 695, 665, 654 cm^--1^. MS (EI): *m*/*z* 267 \[M\]^+^. Anal. calcd for C~16~H~17~N~3~O: C, 71.89; H, 6.41; N, 15.72; O, 5.98. Found: C, 71.72; H, 6.60; N, 15.68.

### 2,2-Dimethyl-4-phenyl-5-(1*H*-pyrrol-2-yl)-2*H*-imidazole 1-Oxide (**3d**) {#sec4.3.4}

Yield: 170 mg (67%), mp = 99--104 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.57 (s, 6H); 5.81--5.83 (m, 1H); 6.09--6.11 (m, 1H); 7.01--7.03 (m, 1H); 7.53--7.65 (m, 5H); 12.07 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 24.0 (CH~3~); 98.4 (C); 109.4 (CH); 111.6 (CH); 119.4 (C); 121.6 (CH); 128.76 (CH); 128.82 (CH); 129.7 (C); 130.9 (CH); 134.0 (C); 166.1 (C) ppm. IR (DRA): ν 1553, 1479, 1438, 1421, 1390, 1365, 1330, 1194, 1166, 1112, 1067, 1040, 967, 776, 731, 700, 663, 648, 595 cm^--1^. MS (EI): *m*/*z* 253 \[M\]^+^. Anal. calcd for C~15~H~15~N~3~O: C, 71.13; H, 5.97; N, 16.59; O, 6.32. Found: C, 71.30; H, 6.00; N, 16.54.

### 2,2-Dimethyl-4-phenyl-5-(5-phenyl-1*H*-pyrrol-2-yl)-2*H*-imidazole 1-Oxide (**3e**) {#sec4.3.5}

Yield: 197 mg (60%), mp = 125--130 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.62 (s, 6H); 5.98--6.00 (m, 1H); 6.68 (t, 1H, *J* = 3.36); 7.28 (t, 1H, *J* = 7.36); 7.42 (t, 2H, *J* = 7.72); 7.56--7.71 (m, 7H); 12.30 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 24.0 (CH~3~); 98.3 (C); 107.6 (CH); 112.9 (CH); 120.5 (C); 123.9 (CH); 127.1 (CH); 128.1 (CH); 128.2 (CH); 128.9 (CH); 129.0 (C); 130.5 (CH); 130.8 (C); 132.6 (C); 133.0 (C); 164.8 (C) ppm. IR (DRA): ν 3256, 3168, 3146, 3115, 2974, 2933, 1601, 1579, 1519, 1418, 1120, 1042, 931, 736, 696 cm^--1^. MS (EI): *m*/*z* 329 \[M\]^+^. Anal. calcd for C~21~H~19~N~3~O: C, 76.57; H, 5.81; N, 12.76; O, 4.86. Found: C, 76.64; H, 5.76; N, 12.80.

### 2,2-Dimethyl-4-phenyl-5-(4,5,6,7-tetrahydro-1*H*-indol-2-yl)-2*H*-imidazole 1-Oxide (**3f**) {#sec4.3.6}

Yield: 129 mg (42%), mp = 141--146 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.56 (d, 6H, *J* = 6.12); 1.59--1.61 (m, 2H); 1.68--1.70 (m, 2H); 2.30 (t, 2H, *J* = 5.82); 2.60 (t, 2H, *J* = 6.00); 5.58 (d, 1H, *J* = 2.04); 7.54--7.63 (m, 5H); 11.60 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): 22.2 (CH~2~); 22.51 (CH~2~); 22.54 (CH~2~); 23.0 (CH~2~); 24.0 (CH~3~); 97.4 (C); 110.0 (CH); 117.2 (C); 117.9 (C); 128.0 (CH); 128.1 (CH); 128.9 (C); 130.2 (CH); 130.4 (C); 133.5 (C); 165.3 (C) ppm. IR (DRA): ν 2932, 1522, 1489, 1443, 1407, 1320, 1303, 1260, 1237, 1170, 1144, 1092, 1073, 1003, 975, 922, 803, 772, 696, 655 cm^--1^. MS (EI): *m*/*z* 307 \[M\]^+^. Anal. calcd for C~19~H~21~N~3~O: C, 74.24; H, 6.89; N, 13.67; O, 5.20. Found: C, 74.10; H, 7.00; N, 13.76.

### 5-(5-Acetylthiophen-2-yl)-2-ethyl-2-methyl-4-phenyl-2*H*-imidazole 1-Oxide (**3g**) {#sec4.3.7}

Yield: 245 mg (75%), mp = 121--126 °C. *R~f~* 0.1 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.59 (t, 3H, *J* = 7.32); 1.61 (s, 3H); 1.95--2.00 (m, 1H); 2.14--2.19 (m, 1H); 2.53 (s, 3H); 6.97 (d, 1H, *J* = 4.24); 7.58--7.70 (m, 5H); 7.82 (d, 1H, *J* = 4.28) ppm. ^13^C NMR (DMSO-*d*~6~): 6.7 (CH~3~); 23.0 (CH~3~); 26.9 (CH~3~); 30.3 (CH~2~); 102.0 (C); 128.0 (CH); 128.3 (CH); 128.7 (CH); 130.7 (CH); 132.2 (CH); 132.6 (C); 133.1 (C); 133.6 (C); 142.3 (C); 165.6 (C); 191.5 (C) ppm. IR (DRA): ν 1659, 1611, 1575, 1499, 1447, 1381, 1368, 1349, 1306, 1266, 1197, 1148, 944, 812 cm^--1^. MS (EI): *m*/*z* 326 \[M\]^+^. Anal. calcd for C~18~H~18~N~2~O~2~S: C, 66.23; H, 5.56; N, 8.58; O, 9.80; S, 9.82. Found: C, 65.93; H, 5.36; N, 7.95.

### 2-Ethyl-2-methyl-4-phenyl-5-(thiophen-2-yl)-2*H*-imidazole 1-Oxide (**3h**) {#sec4.3.8}

Yield: 170 mg (60%), mp = 83--88 °C. *R~f~* 0.3 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.58 (t, 3H, *J* = 7.28); 1.59 (s, 3H); 1.94--2.01 (m, 1H); 2.10--2.17 (m, 1H); 7.01 (d, 1H, *J* = 3.52); 7.09 (t, 1H, *J* = 4.48); 7.57--7.67 (m, 5H); 7.74 (d, 1H, *J* = 4.8 ppm). ^13^C NMR (DMSO-*d*~6~): 6.7 (CH~3~); 23.1 (CH~3~); 30.1 (CH~2~); 101.0 (C); 126.6 (CH); 127.2 (C); 127.4 (CH); 128.2 (CH); 128.3 (CH); 128.6 (CH); 130.5 (CH); 132.6 (C); 133.4 (C); 166.2 (C) ppm. IR (DRA): ν 3330, 3274, 3213, 3180, 2968, 2855, 1641, 1603, 1537, 1443, 1372, 1180, 1143, 941, 694 cm^--1^. MS (EI): *m*/*z* 284 \[M\]^+^. Anal. calcd for C~16~H~16~N~2~OS: C, 67.58; H, 5.67; N, 9.85; O, 5.63; S, 11.28. Found: C, 67.02; H, 5.43; N, 9.64.

### 2-Ethyl-2-methyl-5-(1-methyl-1*H*-pyrrol-2-yl)-4-phenyl-2*H*-imidazole 1-Oxide (**3i**) {#sec4.3.9}

Yield: 197 mg (70%), mp = 79--84 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.63 (t, 3H, *J* = 7.32); 1.58 (s, 3H); 1.92--1.98 (m, 1H); 2.12--2.17 (m, 1H); 3.49 (s, 3H); 5.98--5.99 (m, 1H); 6.10--6.12 (m, 1H); 7.02 (t, 1H, *J* = 2.12); 7.40--7.43 (m, 2H); 7.49--7.53 (m, 3H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 6.8 (CH~3~); 23.8 (CH~3~); 30.2 (CH~2~); 35.0 (CH~3~); 101.5 (C); 108.2 (CH); 112.5 (CH); 118.4 (C); 125.5 (CH); 127.8 (CH); 128.3 (CH); 131.0 (CH); 131.3 (C); 131.9 (C); 166.2 (C) ppm. IR (DRA): ν 1545, 1505, 1487, 1461, 1447, 1433, 1379, 1350, 1331, 1281, 1179, 954, 721, 693, 660 cm^--1^. MS (EI): *m*/*z* 281 \[M\]^+^. Anal. calcd for C~17~H~19~N~3~O: C, 72.57; H, 6.81; N, 14.94; O, 5.69. Found: C, 72.00; H, 6.86; N, 14.53.

### 2-Ethyl-2-methyl-4-phenyl-5-(1*H*-pyrrol-2-yl)-2*H*-imidazole 1-Oxide (**3j**) {#sec4.3.10}

Yield: 134 mg (50%), mp = 89--94 °C. *R~f~* 0.2 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.60 (t, 3H, *J* = 7.24); 1.57 (s, 3H); 1.94--1.99 (m, 1H); 2.09--2.14 (m, 1H); 5.82 (s, 1H); 6.10 (d, 1H, *J* = 2.64); 7.02 (s, 1H); 7.54--7.64 (m, 5H); 12.08 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 6.8 (CH~3~); 23.2 (CH~3~); 29.9 (CH~2~); 100.4 (C); 109.0 (CH); 111.2 (CH); 118.6 (C); 121.1 (CH); 128.2 (CH); 128.4 (CH); 130.3 (C); 130.4 (CH); 133.4 (C); 166.4 (C) ppm. IR (DRA): ν 3293, 1557, 1446, 1409, 1391, 1362, 1325, 1196, 1114, 1070, 1043, 824, 760, 734, 701, 659, 599 cm^--1^. MS (EI): *m*/*z* 267 \[M\]^+^. Anal. calcd for C~16~H~17~N~3~O: C, 71.89; H, 6.41; N, 15.72; O, 5.98. Found: C, 71.12; H, 6.66; N, 14.67.

### 2-Ethyl-2-methyl-4-phenyl-5-(5-phenyl-1*H*-pyrrol-2-yl)-2*H*-imidazole 1-Oxide (**3k**) {#sec4.3.11}

Yield: 199 mg (58%), mp = 75--80 °C. *R~f~* 0.3 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.64 (t, 3H, *J* = 7.30); 1.61 (s, 3H); 1.98--2.03 (m, 1H); 2.14--2.19 (m, 1H); 5.99--6.00 (m, 1H); 6.68 (t, 1H, *J* = 3.36); 7.29 (t, 1H, *J* = 7.36); 7.42 (t, 2H, *J* = 7.72); 7.58--7.70 (m, 7H); 12.28 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 6.8 (CH~3~); 23.2 (CH~3~); 30.0 (CH~2~); 100.8 (C); 107.8 (CH); 113.1 (CH); 120.2 (C); 124.0 (CH); 127.2 (CH); 128.2 (CH); 128.5 (CH); 129.1 (CH); 130.2 (C); 130.7 (CH); 130.9 (C); 132.8 (C); 133.0 (C); 165.9 (C) ppm. IR (DRA): ν 3449, 2927, 2847, 1601, 1572, 1535, 1487, 1443, 1269, 955, 752, 690, 646, 565 cm^--1^. MS (EI): *m*/*z* 343 \[M\]^+^. Anal. calcd for C~22~H~21~N~3~O: C, 76.94; H, 6.16; N, 12.24; O, 4.66. Found: C, 74.66; H, 6.15; N, 11.74.

### 5-(5-Acetyl-1*H*-pyrrol-2-yl)-2-ethyl-2-methyl-4-phenyl-2*H*-imidazole 1-Oxide (**3l**) {#sec4.3.12}

Yield: 167 mg (54%), mp = 157--162 °C. *R~f~* 0.1 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 0.58 (t, 3H, *J* = 7.28); 1.55 (s, 3H); 1.91--1.96 (m, 1H); 2.08--2.13 (m, 1H); 2.25 (s, 3H); 7.05 (s, 1H); 7.56--7.64 (m, 6H); 12.27 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 6.7 (CH~3~); 23.3 (CH~3~); 25.5 (CH~3~); 30.1 (CH~2~); 100.8 (C); 110.8 (C); 114.5 (CH); 125.7 (CH); 128.2 (CH); 128.5 (CH); 130.5 (CH); 131.5 (C); 131.9 (C); 133.5 (C); 167.2 (C); 187.2 (C) ppm. IR (DRA): ν 3131, 2970, 1658, 1569, 1445, 1360, 1339, 1306, 1186, 1135, 1083, 952, 940, 838, 766, 701, 629 cm^--1^. MS (EI): *m*/*z* 309 \[M\]^+^. Anal. calcd for C~18~H~19~N~3~O~2~: C, 69.88; H, 6.19; N, 13.58; O, 10.34. Found: C, 69.63; H, 6.27; N, 13.36.

### 2-(5-Acetylthiophen-2-yl)-3-phenyl-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (3m) {#sec4.3.13}

Yield: 246 mg (70%), mp = 163--168 °C. *R~f~* 0.3 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.40--1.43 (m, 1H); 1.56 (d, 2H, *J* = 12.36); 1.72--1.89 (m, 5H); 2.03--2.10 (m, 2H); 2.52 (s, 3H); 6.96 (d, 1H, *J* = 4.24); 7.58--7.70 (m, 5H); 7.81 (d, 1H, *J* = 4.28) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.7 (CH~2~); 24.2 (CH~2~); 26.8 (CH~3~); 34.4 (CH~2~); 101.8 (C); 127.8 (CH); 128.3 (CH); 128.5 (CH); 130.4 (CH); 131.6 (C); 132.0 (CH); 133.3 (C); 133.9 (C); 142.1 (C); 164.7 (C); 191.3 (C) ppm. IR (DRA): ν 2933, 2921, 2860, 1650, 1560, 1446, 1383, 1363, 1309, 1273, 1196, 959, 818, 773, 707, 695, 657 cm^--1^. MS (EI): *m*/*z* 352 \[M\]^+^. Anal. calcd for C~20~H~20~N~2~O~2~S: C, 68.16; H, 5.72; N, 7.95; O, 9.08; S, 9.10. Found: C, 68.15; H, 5.66; N, 7.56.

### 3-Phenyl-2-(thiophen-2-yl)-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (3n) {#sec4.3.14}

Yield: 202 mg (65%), mp = 179--184 °C. *R~f~* 0.4 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.44--1.52 (m, 3H); 1.80--1.88 (m, 5H); 7.04 (d, 2H, *J* = 3.24); 7.56--7.67 (m, 6H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.5 (CH~2~); 24.1 (CH~2~); 34.4 (CH~2~); 100.7 (C); 126.1 (CH); 127.1 (CH); 127.3 (C); 127.8 (CH); 128.0 (CH); 128.2 (CH); 130.0 (CH); 131.3 (C); 133.5 (C); 165.1 (C) ppm. IR (DRA): ν 3063, 2933, 2860, 1566, 1496, 1477, 1444, 1422, 1383, 1359, 1339, 1324, 1292, 959, 770, 735, 702, 659, 629 cm^--1^. MS (EI): *m*/*z* 310 \[M\]^+^. Anal. calcd for C~18~H~18~N~2~OS: C, 69.65; H, 5.84; N, 9.02; O, 5.15; S, 10.33. Found: C, 68.87; H, 5.69; N, 8.71.

### 2-(1-Methyl-1*H*-pyrrol-2-yl)-3-phenyl-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (**3o**) {#sec4.3.15}

Yield: 184 mg (60%), mp = 157--162 °C. *R~f~* 0.3 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.40--1.52 (m, 3H); 1.83--1.88 (m, 5H); 2.02--2.09 (m, 2H); 3.46 (s, 3H); 6.00--6.02 (m, 1H); 6.10--6.11 (m, 1H); 7.00 (t, 1H, *J* = 2.06); 7.41 (t, 2H, *J* = 7.44); 7.49--7.54 (m, 3H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.6 (CH~2~); 24.3 (CH~2~); 34.5 (CH~3~); 34.8 (CH~2~); 101.2 (C); 107.9 (CH); 112.2 (CH); 118.3 (C); 125.0 (CH); 127.6 (CH); 128.0 (CH); 130.0 (C); 130.6 (CH); 132.1 (C); 165.3 (C) ppm. IR (DRA): ν 2941, 2927, 1544, 1503, 1487, 1443, 1377, 1350, 1329, 1278, 1167, 961, 728, 688, 675, 658, 609 cm^--1^. MS (EI): *m*/*z* 307 \[M\]^+^. Anal. calcd for C~19~H~21~N~3~O: C, 74.24; H, 6.89; N, 13.67; O, 5.20. Found: C, 74.26; H, 7.00; N, 13.60.

### 3-Phenyl-2-(1*H*-pyrrol-2-yl)-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (**3p**) {#sec4.3.16}

Yield: 135 mg (46%), mp = 195--200 °C. *R~f~* 0.4 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.38--1.49 (m, 3H); 1.75--1.88 (m, 5H); 2.10 (t, 2H, *J* = 11.64); 5.81 (s, 1H); 6.09 (d, 1H, *J* = 2.76); 7.01 (s, 1H); 7.53--7.64 (m, 5H); 12.07 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.9 (CH~2~); 24.4 (CH~2~); 34.4 (CH~2~); 100.2 (C); 108.9 (CH); 111.1 (CH); 118.9 (C); 121.0 (CH); 128.26 (CH); 128.28 (CH); 129.3 (C); 130.3 (CH); 133.7 (C); 165.6 (C) ppm. IR (DRA): ν 3284, 2943, 2922, 2851, 1498, 1441, 1408, 1392, 1373, 1332, 1113, 1088, 1058, 996, 729, 696 cm^--1^. MS (EI): *m*/*z* 293 \[M\]^+^. Anal. calcd for C~18~H~19~N~3~O: C, 73.69; H, 6.53; N, 14.32; O, 5.45. Found: C, 73.54; H, 6.55; N, 14.27.

### 3-Phenyl-2-(4,5,6,7-tetrahydro-1*H*-indol-2-yl)-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (**3q**) {#sec4.3.17}

Yield: 132 mg (40%), mp = 167--172 °C. *R~f~* 0.4 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.43 (d, 2H, *J* = 12.64); 1.59--1.84 (m, 10H); 2.06--2.12 (m, 2H); 2.29 (d, 2H, *J* = 5.56); 2.58 (d, 2H, *J* = 5.8); 5.55 (d, 1H, *J* = 1.16); 7.53--7.62 (m, 5H); 11.62 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.1 (CH~2~); 22.5 (CH~2~); 22.6 (CH~2~); 23.0 (CH~2~); 24.3 (CH~2~); 34.3 (CH~2~); 99.5 (C); 109.8 (CH); 117.2 (C); 117.8 (C); 128.0 (CH); 129.0 (C); 130.0 (CH); 130.2 (C); 133.7 (C); 165.5 (C) ppm. IR (DRA): ν 2924, 2851, 1601, 1538, 1489, 1442, 1336, 1267, 1233, 1184, 1009, 971, 954, 698, 566 cm^--1^. MS (EI): *m*/*z* 347 \[M\]^+^. Anal. calcd for C~22~H~25~N~3~O: C, 76.05; H, 7.25; N, 12.09; O, 4.60. Found: C, 76.14; H, 7.30; N, 12.11.

### 2-(5-Acetyl-1*H*-pyrrol-2-yl)-3-phenyl-1,4-diazaspiro\[4.5\]deca-1,3-diene 1-Oxide (**3r**) {#sec4.3.18}

Yield: 147 mg (44%), mp = 195--200 °C. *R~f~* 0.1 (heptane/EtOAc, 6:4). ^1^H NMR (DMSO-*d*~6~ + CCl~4~): δ 1.42 (d, 2H, *J* = 12.16); 1.79 (t, 6H, *J* = 14.58); 2.06 (t, 2H, *J* = 11.16); 2.24 (s, 3H); 7.04 (s, 1H); 7.56--7.64 (m, 6H); 12.24 (s, 1H) ppm. ^13^C NMR (DMSO-*d*~6~): δ 22.9 (CH~2~); 24.5 (CH~2~); 25.5 (CH~3~); 34.6 (CH~2~); 100.7 (C); 111.1 (C); 114.6 (CH); 125.8 (CH); 128.3 (CH); 128.4 (CH); 130.4 (CH); 130.9 (C); 131.4 (C); 133.8 (C); 166.4 (C); 187.2 (C) ppm. IR (DRA): ν 3236, 2938, 1647, 1561, 1442, 1367, 1331, 1300, 1236, 1065, 1002, 831, 786, 773, 710 cm^--1^. MS (EI): *m*/*z* 335 \[M\]^+^. Anal. calcd for C~20~H~21~N~3~O~2~: C, 71.62; H, 6.31; N, 12.53; O, 9.54. Found: C, 70.00; H, 6.53; N, 11.59.

General Procedure for the H/D Exchange Control Experiments {#sec4.4}
----------------------------------------------------------

The hydrogen--deuterium exchange control experiments were carried out according to the literature procedure.^[@ref19]^ The deuteration reactions of either 2*H*-imidazole 1-oxide **1a** or 2-acetylthiophene **2b** separately carried out using the conditions noted in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. Heavy water D~2~O (20.0 mmol) was used as a deuterium source. All reaction mixtures were refluxed at 110--120 °C for 24 h in 1,4-dioxane (5 mL). Then, the mixture was cooled to room temperature, filtered through neutral alumina, and concentrated in vacuo. The obtained residues were individually analyzed by means of ^1^H NMR spectroscopy.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b02916](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b02916).^1^H and ^13^C NMR spectra of **3a--r**; ^1^H--^13^C heteronuclear single quantum coherence, ^1^H--^13^C heteronuclear multiple bond correlation, and ^1^H--^1^H nuclear Overhauser effect spectroscopy 2D NMR spectra of **3c**; ^1^H NMR spectra of reaction mixtures, isolated during the H/D exchange control experiments ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02916/suppl_file/ao8b02916_si_001.pdf))
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